Atomoxetine-Associated Hemospermia: A Case Report

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Atomoxetine is the only nonstimulant medicationapproved by the U.S. Food and Drug Administration for thetreatment of attention-deficit/hyperactivity disorder (ADHD) inchildren, adolescents, and adults. Since its approval in 2002, ithas been widely prescribed and has been associated with a lowoverall incidence of adverse effects. The 4 most common adverseeffects include dry mouth, insomnia, nausea, and erectiledysfunction. The following case report describes a novel adverseeffect associated with atomoxetine—hemospermia.